Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 6/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11208340 | 0.93 | TAAR1 (0.54) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL29127699 | 0.91 | MGLL (0.56) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL30695738 | 0.91 | MGLL (0.56) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL30081968 | 0.91 | MGLL (0.56) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL30081969 | 0.91 | MGLL (0.56) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL6944890 | 0.86 | TAAR1 (0.60) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL4967651 | 0.85 | TAAR1 (0.65) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL3800530 | 0.85 | TAAR1 (0.65) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL8401990 | 0.83 | MGLL (0.66) | TAAR1MPOSLC6A4HSPA5MGLL | |
| SCHEMBL10438887 | 0.83 | TAAR1 (0.62) | TAAR1MPOSLC6A4HSPA5MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105987971-B | Separation and determination method of dapoxetine hydrochloride intermediate SM1 and related impurities | 重庆华邦制药有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-108430979-A | Double triazole compounds with antibiont film and anti-corrosion performance | 土伦·瓦尔大学 | 2018-08-21 | — | — | CN | disclosed |
| CN-105505525-A | Phenolic amine antioxidant and preparation method and application thereof | NINGBO INST MAT TECH & ENG CAS | 2016-04-20 | — | — | CN | disclosed |
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| CN-101258138-B | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV | 2013-06-12 | — | — | CN | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| CN-101258138-A | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV (FR) | 2008-09-03 | — | — | CN | disclosed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717235-A2 | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
| EP-1717234-A1 | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH1 | TAAR1 37/4885MPO 2746/4885SLC6A4 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.